(Q43819297)

27 November 2017

title

Anthrax vaccine: short-term safety experience in humans (English)

1 reference

27 November 2017

0 references

Pittman PR

1

1 reference

27 November 2017

Gibbs PH

series ordinal

2

1 reference

27 November 2017

Cannon TL

series ordinal

3

1 reference

27 November 2017

Friedlander AM

series ordinal

4

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

27 November 2017

1 reference

27 November 2017

volume

20

1 reference

27 November 2017

issue

5-6

1 reference

27 November 2017

page(s)

972-978

1 reference

Clinical recognition and management of patients exposed to biological warfare agents

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900387-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900387-5

1 reference

7 January 2021

Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900387-5

7 January 2021

The Sverdlovsk anthrax outbreak of 1979

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900387-5

7 January 2021

Iraq's biological weapons. The past as future?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900387-5

7 January 2021

Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900387-5

7 January 2021

Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900387-5

7 January 2021

Field Evaluation of a Human Anthrax Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900387-5

7 January 2021

The use of anthrax antigen to immunise man and monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900387-5

7 January 2021

Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900387-5

7 January 2021

The Vaccine Adverse Event Reporting System (VAERS)

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900387-5

7 January 2021

10.1016/S0264-410X(01)00387-5

Identifiers

DOI

1 reference

27 November 2017

1 reference